DaVita’s index additions put recent stock performance in context

DaVita (DVA) has been added to several Russell value benchmarks, including the Russell 1000 Value and Russell Midcap Value indexes, a shift that puts the dialysis provider squarely on many institutional radars.

The stock has logged a 25% gain over the past month and 61.4% over the past 3 months, while broader investor attention has already been building around its earnings, Integrated Kidney Care initiatives and technology focused scheduling tools.

Looking beyond the recent index additions, DaVita’s share price has shown strong momentum, with a 7 day share price return of 10.1%, a 30 day share price return of 25.0% and a year to date share price return of 105.1%. The 1 year total shareholder return of 64.8% and 3 year total shareholder return of 130.4% indicate that recent gains are building on a longer period of investor interest, supported by strong quarterly results, Deutsche Bank’s rating upgrade and continued progress in Integrated Kidney Care and technology initiatives.

If DaVita’s move has you thinking about where else capital is flowing in healthcare, it may be worth scanning other kidney and treatment focused companies using our healthcare AI stocks screener via 40 healthcare AI stocks.

With DaVita now trading well above analyst price targets and fresh index inclusion drawing in more capital, the key question is simple: is the recent surge overdone, or are markets just starting to price in future growth?

Most Popular Narrative: 21.3% Overvalued

DaVita closed at $234.91 while the most followed narrative puts fair value at $193.71, using an 8.08% discount rate to frame that gap.

The aging population and rising rates of diabetes and hypertension continue to fuel steady underlying demand for dialysis, and management reaffirmed their belief in a return to 2% annual treatment growth over time, suggesting upside to revenue as volumes recover from temporary disruptions. Ongoing investments in technology, AI, and data analytics are driving structural cost reductions through improved operational efficiency and enhanced clinical outcomes, which management expects to support margin improvement even in periods of flat or negative volume growth.

Curious how this cash flow story supports a lower fair value than today’s price? The narrative leans heavily on measured revenue growth, firmer margins and a reset earnings multiple. The detailed assumptions behind those inputs are where the real tension sits.

Result: Fair Value of $193.71 (OVERVALUED)

However, DaVita’s story still hinges on sensitive assumptions, with reimbursement pressures and persistently elevated patient mortality both capable of quickly challenging this cash flow narrative.

Another View: DaVita’s valuation through earnings multiples

While the narrative points to DaVita trading around 21.3% above a $193.71 fair value, the current P/E of 19.9x paints a different picture. It sits well below the US Healthcare industry at 25.6x, the peer average at 39.4x and an estimated fair ratio of 26.1x, which points to less downside implied by earnings multiples. The tension for you is clear: which signal feels more reasonable?

Next Steps

If this mix of optimism and concern around DaVita leaves you undecided, consider reviewing the underlying data now so you can shape your own view with 3 key rewards and 2 important warning signs

Looking for more DaVita sized investment ideas?

If DaVita’s story has sharpened your focus on where to put fresh capital next, do not stop here. Broaden your watchlist with targeted ideas that fit your style.

• Spot potential mispricings early by scanning companies that combine quality fundamentals with lower expectations using the 43 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies with higher yields and resilience through the 7 dividend fortresses.
• Prioritise capital preservation by checking companies that carry sturdier balance sheets and lower overall risk in the 75 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.